Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

Why is Warner Bros. Discovery splitting into two companies? How will US-China trade talks in London impact markets? What caused Bitcoin transaction activity to hit a low? Why did Trump deploy National Guard to Los Angeles protests? How will OpenAI’s $10B revenue milestone affect AI industry? What are the implications of Apple’s WWDC 2025 redesign? Why did Tesla receive stock downgrades amid Musk-Trump feud?

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

benzinga.com/news/health-care/25/06/45842636/nano-cap-polypids-lead-drug-candidate-cuts-surgical-infection-risk-by-38-in-phase-3-trial

PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
The SHIELD II trial is designed to assess the efficacy…

This story appeared on benzinga.com, 2025-06-09 16:53:14.